Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 3Terminated 2Withdrawn 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Melanoma 17Carcinoma, Non-Small-Cell Lung 13Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Head and Neck Neoplasms 4Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Hematologic Neoplasms 2Esophageal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Resectable Non-Small Cell Lung Cancer 1

Interventions

spartalizumab 1Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Turcot syndrome × Nivolumab × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡